Table 1.
Relationship of SMC1A phosphorylation expression and clinicopathological parameters in liver cancer patients (n = 78)
| Characteristic | SMC1A phosphorylation immunostaining | ||
|---|---|---|---|
| Low (0-4) | High (5-9) | ||
| N (28) | N (50) | P | |
| Gender (N) | 0.477 | ||
| Male | 26 (92.9%) | 44 (88.0%) | |
| Female | 2 (7.1%) | 6 (12.0%) | |
| Age (years) | 51.64 ± 9.56 | 54.76 ± 10.65 | 0.190 |
| Grade | 0.168 | ||
| Ⅰ-Ⅱ | 22 (78.6%) | 32 (64.0%) | |
| Ⅲ | 6 (21.4%) | 18 (36.0%) | |
| Clinical stages | |||
| Ⅰ-Ⅱ | 18 (64.3%) | 20 (40.0%) | 0.040 |
| Ⅲ-Ⅳ | 10 (35.7%) | 30 (60.0%) | |
| Lymph node metasis | 0.322 | ||
| N0 | 28 (100.0%) | 49 (98.0%) | |
| N1 | 0 (0.0%) | 1 (0%) | |
| Distant metasis | 0.322 | ||
| M0 | 28 (100.0%) | 49 (98.0%) | |
| M1 | 0 (0.0%) | 1 (0%) | |
| Cirrhosis | 0.295 | ||
| No | 15 (53.6%) | 33 (66.0%) | |
| Yes | 13 (46.4%) | 17 (34.0%) | |